The Hadassah Medical Organization, the Israel Institute for Biological Research (IIBR) and Tera Novel, an Israeli start-up company, have collaboratively developed an innovative antiviral and antibacterial mask, which contains a disinfectant that has been proven to be 99.99 percent effective in killing the coronavirus.

Called GERMS OVER, the mask’s patented technology has been under development at IIBR for a number of years. Its formula neutralizes resistant bacteria and viruses and prevents infection and further spread of the disease. Tested in a dedicated department at IIBR, the technology and mask were recently approved by Israel’s Ministry of Health.

The Israel Institute for Biological Research also developed Israel’s COVID-19 vaccine, Brilife, which is now launching Phase II clinical trials at Hadassah Hospital Ein Kerem and Tel HaShomer’s Sheba Medical Center. Shortly, the trial will be expanded to other hospitals around the country. During Phase I, about 80 individuals were inoculated with the vaccine at Hadassah and Sheba. No serious side effects were reported.